AstraZeneca Results Presentation Deck

H1 2023 Performance Farxiga Imfinzi Ultomiris Enhertu Calquence Tagrisso Demand for multiple medicines driving H1 growth Breztri Tezspire Strensiq Fasenra Saphnelo Lokelma Koselugo Total Revenue USD million 2,834 1,976 1,364 580 1,185 2,915 307 135 562 744 115 198 159 Growth vs. PY USD million CEO Opening Remarks Financial Results 7 PY = prior year; CER = constant exchange rates; LCM = lifecycle management. Oncology BioPharmaceuticals Rare Disease 729 682 511 376 282 211 128 119 112 82 79 69 58 Growth vs. PY CER% 40% 57% 64% >2x 33% 12% 76% >8x 26% 14% >3x 59% 57% LCM strategy sustaining growth momentum, new launches accelerating globally CEO Closing Remarks

View entire presentation